Royalty Pharma plc
Royalty Pharma plc（RPRX）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
rprx · 股价预测 · 11 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 11 位华尔街分析师
Buy
11 位分析师
共识
评级分布
12 个月目标价
High
$63.00
Consensus
$53.75
-3.8% upside
Low
$45.00
Median: $53.5 · Last Close: $55.87
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$53.75
-3.8% upside
High Target
$63
12.8%
Low Target
$45
-19.5%
Current Price
$55.87
as of today
Based on analyst price targets, the RPRX stock price prediction for the next 12 months ranges from $45 to $63. The consensus RPRX price forecast of $53.75 implies -3.8% upside from the current price of $55.87.
短期股价预测
Bull算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $57.11 | ↑ 2.23% |
1-day model range: $56.98–$57.25. Peak: $57.25 (+2.23%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $75 | +34.0% |
| 2028 | $91 | +63.6% |
| 2029 | $105 | +87.1% |
| 2030 | $114 | +104.5% |
| 2031 | — | +116.9% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RPRX · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-07 | Citigroup | Maintains | Buy→Buy |
| 2026-05-07 | JP Morgan | Maintains | Overweight→Overweight |
| 2026-04-21 | UBS | Maintains | Buy→Buy |
| 2026-04-10 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2026-01-30 | UBS | Upgrade ↑ | Neutral→Buy |
| 2026-01-27 | Citigroup | Maintains | Buy→Buy |
| 2025-12-11 | TD Cowen | Maintains | Buy→Buy |
| 2025-10-10 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2025-07-22 | Citigroup | Maintains | Buy→Buy |
| 2025-07-10 | Morgan Stanley | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Royalty Pharma plc (RPRX) stock. Of the recent 45 rating actions, 5 were upgrades and 1 were downgrades. 11 analysts currently cover RPRX.
分析师推荐趋势
RPRX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 2 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$3.5B
↓ 14.2% YoY
Revenue Next Year
$3.7B
↑ 7.5% YoY
EPS This Year
$5.13
EPS Next Year
$5.62
↑ 9.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast RPRX EPS of $5.13 for the current fiscal year, based on estimates from 4 analysts. The RPRX revenue forecast is $3.5B for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
RPRX 股价预测由两类独立数据源支撑：来自 11 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。RPRX 的共识目标价为 $53.75（-3.8% 上行空间），分析师共识为 Buy。
RPRX 的短期预测（明日）为 $57.11（+2.23%）。 RPRX 对 2027 年的股价预测均值为 $75。 RPRX 对 2030 年的预测区间为 $111–$117。
Royalty Pharma plc 在 NASDAQ 上市，代码 RPRX。RPRX 在 2027 年的整体展望偏积极，在覆盖分析师中约 100% 对应 Buy 共识。
常见问题
RPRX 预测 · 8 个问题根据 11 位华尔街分析师，RPRX 的 12 个月平均目标价为 $53.75，最高 $63.00、最低 $45.00。若有图表，中位目标价可在上方查看。相对当前价 $55.87，隐含约 -3.8% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.